Holles Laboratories, Inc.
Cohasset, Massachusetts, 02025, United States
NCT Number: NCT00029185
This is a compassionate-use treatment study to provide Dehydrex to patients with corneal erosion syndrome who have previously used Dehydrex.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Cohasset, Massachusetts, 02025, United States
This study continues to provide Dehydrex to patients who have received it previously under other studies. Patients continue to be treated with their current dose of Dehydrex. Upward dose adjustments may be made as clinically indicated. Patients undergo eye exams every 3 to 4 months or more often. Downward dose titration will be attempted in patients who are stable, free of symptoms, and willing to attempt downward adjustments. In patients who are able to discontinue the medication, duration of healing will be determined. In those patients who experience a recurrence after discontinuing the medication, Dehydrex will be restarted at a dose higher than the minimum effective dose. After at least 8 weeks of treatment and resolution of symptoms, the dose may again be reduced. Further attempts to discontinue the medication will not be made.
Completion date provided represents the completion date of the grant per OOPD records
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Holles Laboratories, Inc.
Industry
Topical Dehydrex in Treating Recurrent Corneal Erosion
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06636708
Corneal Diseases, Effectiveness of Microdrops
New York, United States
View Trial DetailsNCT07132437
Corneal Diseases, Eye Diseases
Beijing, China
View Trial DetailsNCT04421300
Conjunctival Diseases, Conjunctivitis
Guangzhou, Guangdong, China
View Trial DetailsNCT02348242
Corneal Diseases, Corneal Injuries
Paris, Île-de-France Region, France
View Trial Details